Back to top
more

Armata Pharmaceuticals (ARMP)

(Delayed Data from AMEX)

$2.65 USD

2.65
9,719

+0.08 (2.97%)

Updated Aug 6, 2025 11:28 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

ARMP Soars 72% in a Month Following Infectious Disease Study Success

by Zacks Equity Research

Armata Pharmaceuticals stock surges 72% in a month following superior efficacy results from a phase Ib/IIa study of AP-SA02 for treating an infectious disease.

Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 47.37% and 64.42%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 5.26% and 26.94%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Sangamo (SGMO) delivered earnings and revenue surprises of -27.27% and 29.77%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

New Strong Sell Stocks for May 8th

by Zacks Equity Research

ARMP, COLM and EFSI have been added to the Zacks Rank #5 (Strong Sell) List on May 8, 2025.

Zacks Equity Research

New Strong Sell Stocks for April 28th

by Zacks Equity Research

CCS, ARMP and CABO have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2025.

Zacks Equity Research

New Strong Sell Stocks for April 24th

by Zacks Equity Research

AMPY, CARS and CLB have been added to the Zacks Rank #5 (Strong Sell) List on April 24, 2025.

Zacks Equity Research

New Strong Sell Stocks for April 9th

by Zacks Equity Research

CSIQ, ARMP and DAR have been added to the Zacks Rank #5 (Strong Sell) List on April 9, 2025.

Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 46.43% and 230.33%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Armata Pharmaceuticals (ARMP) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Armata Pharmaceuticals (ARMP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Hyperfine, Inc. (HYPR) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Hyperfine (HYPR) delivered earnings and revenue surprises of 0% and 15.45%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Y-mAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -12.50% and 0.53%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Armata Pharma (ARMP) Stock Surges 130% in a Month: Here's Why

by Zacks Equity Research

Armata Pharma (ARMP) stock skyrockets 130% in a month due to encouraging progress of the company's pathogen-targeting natural and synthetic phage candidates.

Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) Now Trades Above Golden Cross: Time to Buy?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Zacks Equity Research

Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of 7.41% and 44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Ligand Pharmaceuticals (LGND) Q2 Earnings Beat Estimates

by Zacks Equity Research

Ligand (LGND) delivered earnings and revenue surprises of 86.84% and 5.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Morphic Holding, Inc. (MORF) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -2.22% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vericel Corporation (VCEL) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of 15.38% and 7.27%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of -37.93% and 46.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inovio (INO) delivered earnings and revenue surprises of -14.29% and 42.50%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Cue Biopharma, Inc. (CUE) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cue Biopharma, Inc. (CUE) delivered earnings and revenue surprises of 12.12% and 37.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

After Plunging 35.3% in 4 Weeks, Here's Why the Trend Might Reverse for Armata Pharmaceuticals, Inc. (ARMP)

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Equity Research

Here's Why Armata Pharmaceuticals, Inc. (ARMP) Looks Ripe for Bottom Fishing

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?